Atrial FibrillationCOPECNCT05988424
Randomised Comparison of the Octaray and Pentaray Catheters
A study testing Left atrial mapping in people with Atrial Fibrillation, run by University Hospital Southampton NHS Foundation Trust at 1 site in United Kingdom.
Trial summary
In this study we aim to compare the mapping performance in the left atrium of the established Pentaray catheter to the newer Octaray catheter. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Atrial Fibrillation
- What is being tested?
- Left atrial mapping
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 1 Dec 2025to 17 Oct 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients >18 years listed for redo AF ablation on clinical grounds GA or LA/sedation cases
Who cannot join
- Age <18 years Pregnancy Unable or unwilling to consent Mechanical mitral valve Replacement Enrolled in another clinical study that could confound the results of this study (note: patients enrolled in complementary study are eligible for enrolment)
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
University Hospital Southampton
Southampton, Hampshire, SO166YD
About this study
In this study we aim to compare the mapping performance in the left atrium of the established Pentaray catheter to the newer Octaray catheter.
Read the detailed description
Compared with conventional point by point mapping, the use of a multipolar high density Pentaray catheter (Biosense Webster, Diamond Bar, CA, USA) has been found to produce more rapid, accurate maps. This catheter has 20, 2mm2 electrodes. Newer, high density mapping catheters have also been introduced, capable of collecting detailed maps rapidly. Such catheters include the Orion catheter (Boston Scientific, Marlborough, MA, USA) which has 64, 0.4mm2 electrodes and has been shown to be safe and effective in real world usage, and the HD Grid (Abbott Cardiovascular, Lake Forest, IL, USA) which has 16, 1mm electrodes and has been shown to be associated with shorter procedure and fluoroscopy times and better success rates than conventional circular mapping catheters when used for AF ablation.
Of the above high density catheters, the Pentaray is integrated into the Carto3 system. An advantage of this platform for mapping is the ability to use the Tissue Proximity Indicator (TPI) Filter to reduce the number of points collected without contact and improve the accuracy of the subsequent voltage map.
A novel multipolar catheter, iterating on the previous Pentaray catheter is now being introduced: Octaray. This has 48, 0.9mm2 electrodes arranged on 8 splines. In preclinical studies, Octaray has been found to be collect maps faster, at higher density and with greater accuracy for conduction gaps than the Pentaray. The new catheter has been used safely in clinical cases.
Methods This is a randomised, prospective, single centre, interventional study, Thirty patients listed for redo AF ablation procedures on clinical grounds will be included in the study. Procedures will be under conscious sedation or general anaesthetic as per the preference of the operator, as will the mode of transeptal access and sheaths used to deliver the mapping catheter to the left atrium.
At the start of the case, two consecutive LA maps will be taken by the same operator using the Pentaray and Octaray catheters. In both cases, throughout the study the same catheter types will be used. For the Pentaray catheter, this will be the standard 4-4-4 spaced version. The Octaray for the study will be the larger, 20mm spline version, with the 3-3-3-3-3 spacing.
To minimise any learning effect from repeated map collections in the same chamber, patients will be randomly assigned, using block randomisation, as to whether their first LA map will be collected using the Octaray or Pentaray. The randomised group the patient is in will be kept in a sealed envelope which will only be opened on the day of the procedure. All maps will be respiratory gated. The same sheath will be used for both catheters. For the study protocol, maps will be taken with first one mapping catheter and then the alternative. The rhythm during collection will be the same for both maps. Ideally patients would be in sinus rhythm, with maps collected with coronary sinus pacing. If there were challenges maintaining sinus rhythm during mapping, maps can be taken in AF (though not a mixture of rhythms). The setup in terms of window of interest and references will also be identical. The map detail level will be left at 16 for all maps. The map maximum point density will be left as nominal. The fill and colour thresholds will be kept unchanged at nominal values. No ablation will be permitted between the two maps being collected. When the second map is being collected using the alternative catheter, this will be a new map and not a remap and the prior map will be hidden from the operator.
In order to control for any matrix collected by the initial catheter in taking the first map, a completely new study will be used for the second map.
TPI will be on for the entire collection period for both maps. The time when map collection was started, as well as the fluoroscopy time at that point will be noted. These values will also be noted at the end of the map collection. The aim of map collection will be to get entire coverage of the geometry with voltage data. Where this was not possible will be noted. The time for the catheter to start collecting voltage data will also be recorded, to judge the delay in TPI filter accepted points for the two catheters.
LA Map volumes will be collected from Carto3. The pulmonary veins and any left ventricle inadvertently collected will be removed from the geometries to allow quantitative assessment.
Once the mapping phase has been completed, the operator would complete the procedure as to their usual practice.
There will be no follow up needed for the study. Any acute complications will be noted - acute in this case being defined as complications occurring up to 30 days post-procedure.
- Conditions
- Atrial Fibrillation
- Being tested
- Left atrial mapping
- Keywords
- atrial fibrillation, ablation, mapping
- Medical subject headings
- Atrial Fibrillation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Left atrial mappingOther
Creation of a left atrial voltage map
| Study group | Role | What they receive |
|---|---|---|
| Pentaray | Active comparator | Initial map collected with Pentaray Receives: Other: Left atrial mapping |
| Octaray | Active comparator | Initial map collected with Octaray Receives: Other: Left atrial mapping |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to collect left atrial geometry
Time to collect left atrial geometry
Measured: 1 year
Secondary outcomes (5)
Volume of LA geometry
Volume of LA geometry
Measured: 1 year
Map point density
Map point density
Measured: 1 year
Time to start point collection, based on fulfilment of TPI criteria
Time to start point collection, based on fulfilment of TPI criteria
Measured: 1 year
Low voltage area comparison
Low voltage area comparison
Measured: 1 year
Number and size of PVI gaps identified
Number and size of PVI gaps identified
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Aug 2023
- Study start1 Dec 2025
- Primary completion17 Oct 2026
- Study completion17 Oct 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atrial FibrillationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Crossover from one mapping catheter to the other with randomisation as to which catheter is used first
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital Southampton NHS Foundation Trust
- Sponsor type
- University, hospital or other
- Collaborators
- Biosense Webster, Inc.
- Responsible party
- Sponsor
- Investigators
- Waqas Ullah, Principal investigator, University Hospital Southampton NHS Foundation Trust
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05988424
- Sponsor's protocol ID
- RHM CAR0638
- Acronym
- COPEC
- Status last verified
- Oct 2026
- First submitted
- 4 Aug 2023
- Last updated
- 22 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Only anonymised data will be shared
Study at a glance
From the registry record, last updated by the sponsor on 22 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomised Comparison of the Octaray and Pentaray Catheters
- ClinicalTrials.gov ID
- NCT05988424
- Acronym / sponsor ID
- COPEC / RHM CAR0638
- Conditions
- Atrial Fibrillation
- Keywords
- atrial fibrillation, ablation, mapping
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- University Hospital Southampton NHS Foundation TrustUniversity, hospital or other
- Collaborators
- Biosense Webster, Inc.
- Study start
- 1 Dec 2025 (actual)
- Primary completion
- 17 Oct 2026 (actual)
- Study completion
- 17 Oct 2026 (actual)
- First posted
- 14 Aug 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In this study we aim to compare the mapping performance in the left atrium of the established Pentaray catheter to the newer Octaray catheter.
Detailed description
Compared with conventional point by point mapping, the use of a multipolar high density Pentaray catheter (Biosense Webster, Diamond Bar, CA, USA) has been found to produce more rapid, accurate maps. This catheter has 20, 2mm2 electrodes. Newer, high density mapping catheters have also been introduced, capable of collecting detailed maps rapidly. Such catheters include the Orion catheter (Boston Scientific, Marlborough, MA, USA) which has 64, 0.4mm2 electrodes and has been shown to be safe and effective in real world usage, and the HD Grid (Abbott Cardiovascular, Lake Forest, IL, USA) which has 16, 1mm electrodes and has been shown to be associated with shorter procedure and fluoroscopy times and better success rates than conventional circular mapping catheters when used for AF ablation.
Of the above high density catheters, the Pentaray is integrated into the Carto3 system. An advantage of this platform for mapping is the ability to use the Tissue Proximity Indicator (TPI) Filter to reduce the number of points collected without contact and improve the accuracy of the subsequent voltage map.
A novel multipolar catheter, iterating on the previous Pentaray catheter is now being introduced: Octaray. This has 48, 0.9mm2 electrodes arranged on 8 splines. In preclinical studies, Octaray has been found to be collect maps faster, at higher density and with greater accuracy for conduction gaps than the Pentaray. The new catheter has been used safely in clinical cases.
Methods This is a randomised, prospective, single centre, interventional study, Thirty patients listed for redo AF ablation procedures on clinical grounds will be included in the study. Procedures will be under conscious sedation or general anaesthetic as per the preference of the operator, as will the mode of transeptal access and sheaths used to deliver the mapping catheter to the left atrium.
At the start of the case, two consecutive LA maps will be taken by the same operator using the Pentaray and Octaray catheters. In both cases, throughout the study the same catheter types will be used. For the Pentaray catheter, this will be the standard 4-4-4 spaced version. The Octaray for the study will be the larger, 20mm spline version, with the 3-3-3-3-3 spacing.
To minimise any learning effect from repeated map collections in the same chamber, patients will be randomly assigned, using block randomisation, as to whether their first LA map will be collected using the Octaray or Pentaray. The randomised group the patient is in will be kept in a sealed envelope which will only be opened on the day of the procedure. All maps will be respiratory gated. The same sheath will be used for both catheters. For the study protocol, maps will be taken with first one mapping catheter and then the alternative. The rhythm during collection will be the same for both maps. Ideally patients would be in sinus rhythm, with maps collected with coronary sinus pacing. If there were challenges maintaining sinus rhythm during mapping, maps can be taken in AF (though not a mixture of rhythms). The setup in terms of window of interest and references will also be identical. The map detail level will be left at 16 for all maps. The map maximum point density will be left as nominal. The fill and colour thresholds will be kept unchanged at nominal values. No ablation will be permitted between the two maps being collected. When the second map is being collected using the alternative catheter, this will be a new map and not a remap and the prior map will be hidden from the operator.
In order to control for any matrix collected by the initial catheter in taking the first map, a completely new study will be used for the second map.
TPI will be on for the entire collection period for both maps. The time when map collection was started, as well as the fluoroscopy time at that point will be noted. These values will also be noted at the end of the map collection. The aim of map collection will be to get entire coverage of the geometry with voltage data. Where this was not possible will be noted. The time for the catheter to start collecting voltage data will also be recorded, to judge the delay in TPI filter accepted points for the two catheters.
LA Map volumes will be collected from Carto3. The pulmonary veins and any left ventricle inadvertently collected will be removed from the geometries to allow quantitative assessment.
Once the mapping phase has been completed, the operator would complete the procedure as to their usual practice.
There will be no follow up needed for the study. Any acute complications will be noted - acute in this case being defined as complications occurring up to 30 days post-procedure.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
- Model description
- Crossover from one mapping catheter to the other with randomisation as to which catheter is used first
| Arm | Type | Receives |
|---|---|---|
| Pentaray | Active comparator | Other: Left atrial mappingInitial map collected with Pentaray |
| Octaray | Active comparator | Other: Left atrial mappingInitial map collected with Octaray |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Patients >18 years listed for redo AF ablation on clinical grounds GA or LA/sedation cases
Key exclusion criteria (1 listed)
- Age <18 years Pregnancy Unable or unwilling to consent Mechanical mitral valve Replacement Enrolled in another clinical study that could confound the results of this study (note: patients enrolled in complementary study are eligible for enrolment)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Left atrial mappingCreation of a left atrial voltage map | Other | Octaray, Pentaray |
Primary outcome
Time to collect left atrial geometry
Time frame: 1 year
Time to collect left atrial geometry
5 secondary outcomes
Volume of LA geometry
Time frame: 1 year
Map point density
Time frame: 1 year
Time to start point collection, based on fulfilment of TPI criteria
Time frame: 1 year
Low voltage area comparison
Time frame: 1 year
Number and size of PVI gaps identified
Time frame: 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Oct 2026.
- Individual participant dataSharing planned: No. Only anonymised data will be shared
Related trials for Atrial Fibrillation
Active, not recruiting
Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)
Paroxysmal AF
Active, not recruitingObservational study
Concomitant Left Atrial Appendage Closure and Pulsed Field Ablation-Asia
Concomitant Procedures, Atrial Fibrillation
Active, not recruiting
CONVERGE Post-Approval Study (PAS)
Chronic Atrial Fibrillation
Recruiting
Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy
Ischemic Stroke, Atrial Fibrillation
RecruitingPhase 2
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Atrial Fibrillation (AF)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Waqas Ullah principal investigator
University Hospital Southampton NHS Foundation Trust
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Left atrial mapping in people with Atrial Fibrillation, run by University Hospital Southampton NHS Foundation Trust at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to collect left atrial geometry (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Oct 2026.